Table 2

Comparison of NSAID and aspirin use by cases versus controls

Analysis

NSAID users (%)

OR (95% CI)

P value

Cases

Controls

Global (n = 152)^a

NSAIDs and aspirin

27

28

0.93 (0.52 to 1.64)

0.79

NSAIDs

24

21

1.18 (0.64 to 2.19)

0.56

Chronic treatment

4

5

0.86 (0.24 to 2.98)

0.78

Acute treatment

20

16

1.40 (0.69 to 2.92)

0.32

Aspirin

5

10

0.47 (0.16 to 1.22)

0.09

Subgroup analysis

Diabetes (n = 20)^a

NSAIDs

20

5

4.00 (0.40 to 196.99)

0.18

Aspirin

10

5

2.00 (0.40 to 196.99)

0.56

No diabetes (n = 132)^a

NSAIDs

24

23

1.05 (0.55 to 2.00)

0.88

Aspirin

4

11

0.36 (0.10 to 1.05)

0.04^b

Site of infection: lung (n = 71)^a

NSAIDs

14

15

0.90 (0.32 to 2.46)

0.82

Aspirin

7

11

0.63 (0.16 to 2.17)

0.40

Site of infection: urinary tract (n = 30)^a

NSAIDs

27

30

0.83 (0.02 to 3.28)

0.76

Aspirin

3

7

0.50 (0.01 to 9.60)

0.56

Site of infection: skin and soft tissue (n = 16)^a

NSAIDs

31

31

1.00 (0.07 to 13.80)

1.00

Aspirin

0

6

- -

-

Site of infection: other (n = 35)^a

NSAIDs

37

20

2.50 (0.72 to 10.92)

0.11

Aspirin

3

11

0.25 (0.01 to 2.53)

0.18

^aThe n values indicate the number of pairs. ^bThe apparent discordance between the confidence interval (CI) and statistical test results is due to the use of different but asymptotically equivalent statistical methods. NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio.

Legras et al. Critical Care 2009 13:R43   doi:10.1186/cc7766